September 22, 2021 06:56 AM EDTUpdated April 21, 08:44 AM
Startups
Special

The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

John Carroll

Editor & Founder

These days, se­lect­ing a group of pri­vate biotechs for the End­points 11 spot­light be­gins with a sprint to get ahead of IPOs and the M …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times